Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study

Fig. 3

Percentage of patients who achieved primary and secondary outcomes (full analysis set*). p < 0.05 versus placebo for all active treatment groups for all three endpoints, with the exception of ‘≥ 1 flare’, where there was no statistically significant difference between FBX XR 40 mg and placebo. †p < 0.05 versus equivalent-dose IR formulation. FBX febuxostat, IR immediate release, sUA serum uric acid, XR extended release

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us